^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CXCR5-targeted antibody-drug conjugate

    Related drugs:
    1year
    Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model (ASH 2023)
    Loncastuximab teserine had a deleterious effect on several hematologic parameters, which was not observed with VIP924 or polatuzumab vedotin. The efficacy and tolerability observed in this study with VIP924 suggests further testing in human clinical trials is warranted.
    Preclinical
    |
    CD79B (CD79b Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    CD79B expression • CXCR5 expression
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq) • VIP924
    over1year
    CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma (AACR 2023)
    CXCR5 is a highly attractive target in hematological malignancies such as DLBCL, MCL, and FL due to high protein expression and almost no expression in healthy tissues. CXCR5-targeting ADC with KSPi payload showed high potency and superiority to other B-cell-targeted ADCs in vitro on a broad range of lymphoma cell lines. VIP924 with a novel legumain-cleavable linker showed activity in in vivo PDX models from lymphoma patients.
    Clinical
    |
    CD19 (CD19 Molecule) • CD79B (CD79b Molecule) • CD70 (CD70 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    VIP924